Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model (Q47743713)

5 February 2018

title

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model (English)

1 reference

5 February 2018

1 reference

1 reference

Yuliang Sun

1 reference

5 February 2018

Nandini Dey

1 reference

5 February 2018

Melissa Brammer

1 reference

5 February 2018

Pradip De

1 reference

5 February 2018

Brian Leyland-Jones

1 reference

5 February 2018

publication date

1 October 2013

1 reference

5 February 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

5 February 2018

volume

1 reference

5 February 2018

issue

1 reference

5 February 2018

page(s)

733-745

1 reference

5 February 2018

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2233-7

10.1007/S00280-013-2233-7

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018